High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability

Overview

Journal Cancer Discov

Specialty Oncology

Date 2011 Oct 11

PMID 21984976

Citations 265

Authors

Lydia W T Cheung

Bryan T Hennessy

Jie Li

Shuangxing Yu

Andrea P Myers

Bojana Djordjevic

Yiling Lu

Katherine Stemke-Hale

Mary D Dyer

Fan Zhang

Zhenlin Ju

Lewis C Cantley

Steven E Scherer

Han Liang

Karen H Lu

Russell R Broaddus

Gordon B Mills

Affiliations

Soon will be listed here.

Abstract

We demonstrate that phosphatidylinositol 3-kinase (PI3K) pathway aberrations occur in >80% of endometrioid endometrial cancers, with coordinate mutations of multiple PI3K pathway members being more common than predicted by chance. PIK3R1 (p85α) mutations occur at a higher rate in endometrial cancer than in any other tumor lineage, and PIK3R2 (p85β), not previously demonstrated to be a cancer gene, is also frequently mutated. The dominant activation event in the PI3K pathway appears to be PTEN protein loss. However, in tumors with retained PTEN protein, PI3K pathway mutations phenocopy PTEN loss, resulting in pathway activation. KRAS mutations are common in endometrioid tumors activating independent events from PI3K pathway aberrations. Multiple PIK3R1 and PIK3R2 mutations demonstrate gain of function, including disruption of a novel mechanism of pathway regulation wherein p85α dimers bind and stabilize PTEN. Taken together, the PI3K pathway represents a critical driver of endometrial cancer pathogenesis and a novel therapeutic target.

Citing Articles

The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.

Molefi T, Mabonga L, Hull R, Mwazha A, Sebitloane M, Dlamini Z Cells. 2025; 14(5).

PMID: 40072110 PMC: 11898822. DOI: 10.3390/cells14050382.

Understanding the conformational dynamics of PI3Kα due to helical domain mutations: insights from Markov state model analysis.

Jani V, Sonavane U, Sawant S Mol Divers. 2025; .

PMID: 39982680 DOI: 10.1007/s11030-025-11138-1.

High Frequency of Alterations in Ovarian Cancers: Clinicopathological and Molecular Associations.

Rzepecka I, Tysarowski A, Konopka B, Dansonka-Mieszkowska A, Kupryjanczyk J Cancers (Basel). 2025; 17(2).

PMID: 39858051 PMC: 11764438. DOI: 10.3390/cancers17020269.

Exploring potential causal genetic variants and genes for endometrial cancer: Open Targets Genetics, Mendelian randomization, and multi-tissue transcriptome-wide association analysis.

Zhang G, Mao S, Yuan G, Wang Y, Yang J, Dai Y Transl Cancer Res. 2024; 13(11):5971-5982.

PMID: 39697733 PMC: 11651742. DOI: 10.21037/tcr-24-887.

Prognostic and clinicopathological significance of survivin in gynecological cancer.

Chuwa A, Mvunta D Oncol Rev. 2024; 18:1444008.

PMID: 39687493 PMC: 11646728. DOI: 10.3389/or.2024.1444008.

References

Wu H, Shekar S, Flinn R, El-Sibai M, Jaiswal B, Sen K . Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Proc Natl Acad Sci U S A. 2009; 106(48):20258-63. PMC: 2787125. DOI: 10.1073/pnas.0902369106. View

Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, Garcia-Rostan G . Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene. 2002; 21(52):7981-90. DOI: 10.1038/sj.onc.1205924. View

Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y . The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer. 2009; 101(1):145-8. PMC: 2713716. DOI: 10.1038/sj.bjc.6605109. View

Jaiswal B, Janakiraman V, Kljavin N, Chaudhuri S, Stern H, Wang W . Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell. 2009; 16(6):463-74. PMC: 2804903. DOI: 10.1016/j.ccr.2009.10.016. View

Jarboe E, Pizer E, Miron A, Monte N, Mutter G, Crum C . Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol. 2009; 22(3):345-50. PMC: 2649686. DOI: 10.1038/modpathol.2008.197. View

Rabinovsky R, Pochanard P, McNear C, Brachmann S, Duke-Cohan J, Garraway L . p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Mol Cell Biol. 2009; 29(19):5377-88. PMC: 2747981. DOI: 10.1128/MCB.01649-08. View

Gupta S, Ramjaun A, Haiko P, Wang Y, Warne P, Nicke B . Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007; 129(5):957-68. DOI: 10.1016/j.cell.2007.03.051. View

Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N . Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A. 2001; 98(20):11563-8. PMC: 58769. DOI: 10.1073/pnas.201167798. View

He J, de la Monte S, Wands J . The p85beta regulatory subunit of PI3K serves as a substrate for PTEN protein phosphatase activity during insulin mediated signaling. Biochem Biophys Res Commun. 2010; 397(3):513-9. PMC: 2902794. DOI: 10.1016/j.bbrc.2010.05.146. View

10.

Sun H, Enomoto T, Fujita M, Wada H, Yoshino K, Ozaki K . Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol. 2001; 115(1):32-8. DOI: 10.1309/7JX6-B9U9-3P0R-EQNY. View

11.

Alimonti A, Nardella C, Chen Z, Clohessy J, Carracedo A, Trotman L . A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest. 2010; 120(3):681-93. PMC: 2827955. DOI: 10.1172/JCI40535. View

12.

Engelman J, Chen L, Tan X, Crosby K, Guimaraes A, Upadhyay R . Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14(12):1351-6. PMC: 2683415. DOI: 10.1038/nm.1890. View

13.

Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S . Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res. 2001; 7(4):892-5. View

14.

Chagpar R, Links P, Pastor M, Furber L, Hawrysh A, Chamberlain M . Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 2010; 107(12):5471-6. PMC: 2851819. DOI: 10.1073/pnas.0908899107. View

15.

Ueki K, Fruman D, Brachmann S, Tseng Y, Cantley L, Kahn C . Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol. 2002; 22(3):965-77. PMC: 133541. DOI: 10.1128/MCB.22.3.965-977.2002. View

16.

Sun M, Hillmann P, Hofmann B, Hart J, Vogt P . Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A. 2010; 107(35):15547-52. PMC: 2932613. DOI: 10.1073/pnas.1009652107. View

17.

Slomovitz B, Lu K, Johnston T, Coleman R, Munsell M, Broaddus R . A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010; 116(23):5415-9. PMC: 5120730. DOI: 10.1002/cncr.25515. View

18.

Hsu J, Shi Y, Frost P, Yan H, Hoang B, Sharma S . Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene. 2004; 23(19):3368-75. DOI: 10.1038/sj.onc.1207459. View

19.

Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K . PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008; 68(19):8127-36. DOI: 10.1158/0008-5472.CAN-08-0755. View

20.

Dutt A, Salvesen H, Chen T, Ramos A, Onofrio R, Hatton C . Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008; 105(25):8713-7. PMC: 2438391. DOI: 10.1073/pnas.0803379105. View